Assessing the effect of pneumococcal conjugate vaccines: What is the value of routinely collected surveillance data?

The Lancet Infectious Diseases

Volumn 11, Issue 10, 2011, Pages 724-726

  Grijalva, Carlos G ^a   Moore, Matthew R ^b   Griffin, Marie R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

DISEASE SURVEILLANCE; DRUG EFFECT; HEALTH SURVEY; HOSPITAL ADMISSION; HUMAN; MORBIDITY; NOTE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEROTYPE; UNITED KINGDOM; VACCINATION;

EID: 80955177607     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70143-8     Document Type: Letter

References (13)

1. Vaccine Information Management System International Vaccine Access Center, (accessed April 15, 2011). http://www.jhsph.edu/ivac/vims.html.
2. Nuorti JP, Whitney CG Prevention of pneumococcal disease among infants and children- use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 59:1-18. Centers for Disease Control and Prevention.
3. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
4. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007, 369:1179-1186.
5. Grijalva CG, Poehling KA, Nuorti JP, et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 2006, 118:865-873.
6. Lehmann D, Willis J, Moore HC, et al. The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes. Clin Infect Dis 2010, 50:1477-1486.
7. Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 2009, 49:205-212.
8. Rodenburg GD, de Greeff SC, Jansen AG, et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis 2010, 16:816-823.
9. Miller E, Andrews NJ, Waight PA, Slack MPE, George RC Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011, published online May 27. 10.1016/S1473-3099(11)70090-1.
10. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005, 54:893-897. Centers for Disease Control and Prevention.
11. Flasche S, Slack M, Miller E Long term trends introduce a potential bias when evaluating the impact of the pneumococcal conjugate vaccination programme in England and Wales. Euro Surveill 2011, 16:19868.
12. Hanquet G, Lernout T, Vergison A, et al. Impact of conjugate 7-valent vaccination in Belgium: Addressing methodological challenges. Vaccine 2011, 29:2856-2864.
13. Harboe ZB, Benfield TL, Valentiner-Branth P, et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis 2010, 50:329-337.